ga-68 galmydar
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 5, 2022 (NCT05280782)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05625490 | Early Phase 1 (Phase 1) | Nov 11, 2022 | National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Washington University in St. Louis |
| NCT05280782 | Early Phase 1 (Phase 1) | Jan 5, 2022 | National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Washington University in St. Louis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 2 | 0 | 1 | 2022 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 1 | 2022 |
| Washington University in St. Louis | Academic/Hospital | 2 | 2 | 1 | 2022 |
3 organizations
Page 1 / 1